Sandostatin LAR depot 30 MG KTS
Ended Awarded Last action
- Contract number
- SPE2DR26F0XU2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,783
Award facts
- Contract value 100% obligated
- $12,783.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,783.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for Sandostatin LAR Depot 30 mg kits, with an ultimate completion date of December 8, 2025. This non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, regularly fulfills competitively awarded delivery orders through this IDC framework covering diverse pharmaceutical products and medical supplies across multiple therapeutic domains. The company's substantial prime IDV with DLA enables it to supply essential medications, vaccines, and medical commodities to support military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. Sandostatin LAR Depot is a long-acting formulation of octreotide, a somatostatin analog used for treating acromegaly and neuroendocrine tumors, reflecting the specialized medical support provided through this contract vehicle.
Quick answers
Who was awarded contract SPE2DR26F0XU2?
SPE2DR26F0XU2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26F0XU2 worth?
The government has obligated $12,783 on SPE2DR26F0XU2.
Is contract SPE2DR26F0XU2 an order under another contract?
Yes. SPE2DR26F0XU2 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F0XU2 competed?
The extent of competition for SPE2DR26F0XU2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award